Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cuttingedge growth stocks. Studies have shown that stocks with the best gro ...

Given these factors, it shouldn't be surprising that UTHR is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep United Therapeutics on your short list. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have re ...

Core Viewpoint - United Therapeutics (UTHR) is currently viewed as a more attractive investment option compared to Catalent (CTLT) for value investors, based on various valuation metrics and analyst outlooks [2][5]. Valuation Metrics - UTHR has a P/B ratio of 2.67, while CTLT has a P/B ratio of 2.89, indicating that UTHR is relatively undervalued compared to CTLT [4]. - The forward P/E ratio for UTHR is 12.93, significantly lower than CTLT's forward P/E of 49.05, suggesting UTHR is more favorably priced [8]. - UTHR's PEG ratio stands at 1.40, while CTLT's PEG ratio is 1.68, further supporting UTHR's position as a better value investment [8]. Analyst Outlook - UTHR holds a Zacks Rank of 2 (Buy), reflecting a positive earnings estimate revision activity, whereas CTLT has a Zacks Rank of 5 (Strong Sell), indicating a less favorable outlook [2][5]. - UTHR has a Value grade of B, while CTLT has a Value grade of D, highlighting the relative strength of UTHR in terms of value metrics [9].

Core Viewpoint - United Therapeutics has shown significant stock performance, with an 11.6% increase over the past month and a 46.2% rise since the beginning of the year, outperforming both the Zacks Medical sector and the Zacks Medical - Drugs industry [1][2]. Financial Performance - For the current fiscal year, United Therapeutics is projected to achieve earnings of $24.85 per share on revenues of $2.71 billion, reflecting a 25.44% increase in EPS and a 16.46% increase in revenues [2]. - The next fiscal year forecasts earnings of $27.25 per share on revenues of $2.85 billion, indicating a year-over-year change of 9.65% in EPS and 5.16% in revenues [2]. Valuation Metrics - The stock trades at 12.9 times the current fiscal year EPS estimates, below the peer industry average of 15.2 times [7]. - On a trailing cash flow basis, the stock trades at 14.6 times, compared to the peer group's average of 8.7 times [7]. - The PEG ratio stands at 1.4, which does not position the company among the top value stocks [7]. Style Scores - United Therapeutics has a Value Score of B, with Growth and Momentum Scores both rated A, resulting in a combined VGM Score of A [9]. Zacks Rank - The stock holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [10]. - The recommendation suggests that stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B are favorable, indicating potential for further gains for United Therapeutics [11]. Earnings Surprises - The company has a strong track record of positive earnings surprises, having met or exceeded earnings consensus estimates in the last four quarters [12]. - In the latest earnings report on May 1, 2024, United Therapeutics reported an EPS of $6.17, surpassing the consensus estimate of $5.63 [12].

United Therapeutics (UTHR) announced full enrolment in the phase III TETON 2 study evaluating a nebulized version of Tyvaso (treprostinil) in patients with idiopathic pulmonary fibrosis (IPF), a scarring disease of the lungs. The TETON 2 study is now enrolled with a total of 597 patients. Top-line data from this study is expected in second-half 2025. The FDA has already approved Tyvaso as an inhalation solution (nebulized) and dry powder inhaler (DPI) for treating pulmonary arterial hypertension (PAH) and p ...

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading activities [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as recommendations or advice for any financial actions [1]. - The content is not tailored to individual financial situations or needs, highlighting the necessity for users to apply their own discretion [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - Users are encouraged to perform their own research and understand the risks involved before investing in any financial instruments [1].

Company Overview - United Therapeutics Corporation is based in Silver Spring, MD and markets four medicines in the United States for treating pulmonary arterial hypertension (PAH): Remodulin, Orenitram, Tyvaso, and Adcirca [7] Earnings Estimates - Seven analysts have revised their earnings estimates upwards for fiscal 2024, with the Zacks Consensus Estimate increasing by $0.85 to $24.62 per share [8] - United Therapeutics boasts an average earnings surprise of 12.4% [8] Investment Ratings - United Therapeutics has a Zacks Rank of 3 (Hold) and a Value Style Score of B, indicating attractive valuation metrics such as a forward P/E ratio of 11.23 [20] - The company also has a VGM Score of A, suggesting strong overall performance potential [20][21] Investment Strategy - To maximize investment returns, it is recommended to consider stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [18] - Stocks with a 3 (Hold) rank should also have Style Scores of A or B to ensure upside potential [18]

Group 1: Zacks Style Scores Overview - Zacks Style Scores are complementary indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks with the best chances of outperforming the market over the next 30 days [2][3] - Each stock is assigned a rating from A to F, with A indicating the highest potential for outperformance [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, which combines all three styles [3][4][5] Group 2: Value Score - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Group 3: Growth Score - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] Group 4: Momentum Score - The Momentum Score helps investors capitalize on price trends, using factors like one-week price change and monthly earnings estimate changes [4] Group 5: VGM Score - The VGM Score combines Value, Growth, and Momentum Scores to provide a comprehensive indicator for stock selection [5] Group 6: Zacks Rank - The Zacks Rank is a proprietary stock-rating model based on earnings estimate revisions, helping investors build successful portfolios [6] - Stocks rated 1 (Strong Buy) have produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7] Group 7: Stock to Watch - United Therapeutics (UTHR) - United Therapeutics Corporation markets four medicines for pulmonary arterial hypertension, including Remodulin, Orenitram, Tyvaso, and Adcirca [10] - UTHR is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A and a Momentum Style Score of A, having increased 4.9% over the past four weeks [11] - The Zacks Consensus Estimate for UTHR's fiscal 2024 earnings has risen by $1.16 to $24.62 per share, with an average earnings surprise of 12.4% [11][12]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [3] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Score assesses a company's future prospects through projected earnings, sales, and cash flow [5] Momentum Score - The Momentum Score identifies stocks with favorable price trends using recent price changes and earnings estimate revisions [6] VGM Score - The VGM Score combines all three Style Scores, highlighting stocks with attractive value, growth, and momentum characteristics [7] Zacks Rank - The Zacks Rank is a proprietary model based on earnings estimate revisions, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Stock to Watch: United Therapeutics (UTHR) - United Therapeutics Corporation specializes in treatments for pulmonary arterial hypertension (PAH) with four marketed medicines [12] - UTHR holds a Zacks Rank of 3 (Hold) and a VGM Score of A, with a Value Style Score of B, supported by a forward P/E ratio of 11.37 [13] - Recent upward revisions in earnings estimates have increased the Zacks Consensus Estimate to $24.20 per share, with an average earnings surprise of 12.4% [13][14]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed a ...